Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors
Tóm tắt
Given the multiple targets of metformin within cells, the mechanism by which it may exert a growth-inhibitory action on pituitary tumor cells in vitro remains to be explored. Previous research stressed metformin-induced changes in the activity of signaling pathways regulating cell growth and cell death. In this work, we investigated the effects of metformin on cell viability markers related to cell metabolic activity in rat pituitary tumor cells versus rat myogenic precursors as a model of normal proliferating somatic cells. We designed our experiments in order to use the MTT reduction as a marker of cellular reductive activity and the total cellular ATP levels as a marker of energy supply during short incubations with different metabolic substrates (sodium pyruvate, D-glucose, L-glutamine, sodium citrate). Then, we extended the analysis to extracellular glucose consumption, extracellular medium acidification and pyruvate dehydrogenase (PDH) complex activity. Metformin was found to be effective in both cell types at the same concentrations, although the outcome of the treatment was quite the opposite. Unexpectedly, metformin increased the viability of subconfluent rat myoblasts. Rat pituitary tumor cells and myoblasts differed in the utilization of distinct metabolic substrates and the PDH complex activity. Metformin actions on reductive activity and ATP production were substrate-dependent. Overall, this work points out that metformin actions at the cellular level depend on metabolic features and metabolic requirements of cells. The pyruvate metabolic branch point is most likely to play a main role in the variability of cell response to metformin.
Tài liệu tham khảo
S. Thakur, B. Daley, J. Klubo-Gwiezdzinska, The role of the antidiabetic drug metformin in the treatment of endocrine tumors. J. Mol. Endocrinol. 63, R17–R35 (2019)
G. Tulipano, M. Giovannini, M. Spinello, V. Sibilia, A. Giustina, D. Cocchi, AMP-activated protein kinase regulates normal rat somatotroph cell function and growth of rat pituitary adenomatous cells. Pituitary 14, 242–252 (2011)
J. An, X. Pei, Z. Zang, Z. Zhou, J. Hu, X. Zheng, Y. Zhang, J. He, L. Duan, R. Shen et al. Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. Oncotarget 8, 37538–37549 (2017)
L. Faggi, A. Giustina, G. Tulipano, Effects of metformin on cell growth and AMPK activity in pituitary adenoma cell cultures, focusing on the interaction with adenylyl cyclase activating signals. Mol. Cell. Endocrinol. 470, 60–74 (2018)
M.C. Vázquez-Borrego, A.C. Fuentes-Fayos, A.D. Herrera Martinez, F.L. L-Lopez, A. Ibanez-Costa, P. Moreno-Moreno, M.R. Alhambra-Expósito, A. Barrera-Martín, C. Blanco-Acevedo, E. Dios et al. Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and –independent mechanisms. J. Clin. Endocrinol. Metabol. 104, 3501–3513 (2019)
S. Andrzejewski, S.P. Gravel, M. Pollak, J. St-Pierre, Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metabol. 2, 12 (2014)
A.K. Madiraju, D.M. Erion, Y. Rahimi, X.M. Zhang, D.T. Braddock, R.A. Albright, B.J. Prigaro, J.L. Wood, S. Bhanot, M.J. MacDonald et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546 (2014)
A.R. Cameron, L. Logie, K. Patel, S. Erhardt, S. Bacon, P. Middleton, J. Harthill, C. Forteath, J.T. Coats, C. Kerra et al. Metformin selectively targets redox control of complex I energy transduction. Redox Biol. 14, 187–197 (2018)
B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, F. Andreelli, Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. 122, 253–270 (2012)
V.S. Vytla, R.S. Ochs, Metformin increases mitochondrial energy formation in L6 muscle cell cultures. J. Biol. Chem. 288, 20369–20377 (2013)
A. Alshawi, L. Agius, Low metformin causes a more oxidized mitochondrial NADH/NAD redox state in hepatocytes and inhibits gluconeogenesis by a redox-independent mechanism. J. Biol. Chem. 294, 2839–2853 (2018)
S. Thakur, B. Daley, K. Gaskins, V.V. Vasko, M. Boufraqech, D. Patel, C. Sourbier, J. Reece, S.Y. Cheng, E. Kebebew et al. Metformin targets Mitochondrial Glycerophosphate Dehydrogenase (mGPDH) to control Rate of Oxidative Phosphorylation and growth of thyroid cancer in vitro and in vivo. Clin. Cancer Res. 24, 4030–4043 (2018)
M.J. Rardin, S.E. Wiley, R.K. Naviaux, A.N. Murphy, J.E. Dixon, Monitoring phosphorylation of the pyruvate dehydrogenase complex. Anal. Biochem. 389, 157–164 (2009)
N.H. Jeoung, Pyruvate dehydrogenase kinases: therapeutic targets for diabetes and cancers. Diabetes Metab. J. 39, 188–197 (2015)
S. Takahashi, T. Abe, J. Gotoh, Y. Fukuuchi, Substrate-dependence of reduction of MTT: a tetrazolium dye differs in cultured astroglia and neurons. Neurochem. Int. 40, 441–448 (2002)
G. Tulipano, L. Faggi, M. Losa, P. Mortini, M. Spinello, V. Sibilia, F. Pagani, D. Cocchi, A. Giustina, Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells. Mol. Cell. Endocrinol. 365, 197–206 (2013)
E. Vega-Avila, M.K. Pugsley, An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. Proc. Western Pharmacol. Soc. 54, 10–14 (2011)
G. Tulipano, L. Faggi, A. Cacciamali, M. Spinello, D. Cocchi, A. Giustina, Role of AMP-activated protein kinase (AMPK) activators in antiproliferative multi-drug pituitary tumor therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells. J. Neuroendocrinol. 27, 20–32 (2015)
H. Lin, S. Patel, V.S. Affleck, I. Wilson, D.M. Turnbull, A.R. Joshi, R. Maxwell, E.A. Stoll, Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro-oncology 19, 43–54 (2017)
T. Bender, J.C. Martinou, The mitochondrial pyruvate carrier in health and disease: to carry or not to carry? Biochimica et Biophysica Acta 1863, 2436–2442 (2016)
K. Linher-Melville, G. Singh, The complex roles of STAT3 and STAT5 in maintaining redox balance: Lessons from STAT-mediated xCT expression in cancer cells. Mol. Cell. Endocrinol. 451, 40–52 (2017)
M.J. MacDonald, M.J. Longacre, T.F. Warner, A. Thonpho, High level of ATP citrate lyase expression in human and rat pancreatic islets. Hormone Metabol. Res. 45, 391–393 (2013)
S.M. Fendt, E.L. Bell, M.A. Keibler, S.M. Davidson, G.J. Wirth, B. Fiske, J.R. Mayers, M. Schwab, G. Bellinger, A. Csibi et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 73, 4429–4438 (2013)
K. Urakami, V. Zangiacomi, C. Yamaguchi, M. Kusuhara, Impact of 2-deoxy-D-glucose on the target metabolome profile of a human endometrial cancer cell line. Biomed. Res. 34, 221–229 (2013)
Y.W. Choi, I.K. Lim, Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells. Cancer Lett. 346, 300–308 (2014)
I. Ben Sahra, K. Laurent, S. Giuliano, F. Larbret, G. Ponzio, P. Gounon, Y. Le Marchand-Brustel, S. Giorgetti-Peraldi, M. Cormont, C. Bertolotto et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70, 2465–2475 (2010)
M. Elgendy, M. Cirò, A. Hosseini, J. Weiszmqann, L. Mazzarella, E. Ferrari, R. Cazzoli, G. Curigliano, A. DeCensi, B. Bonanni et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3b-MCL-1 axis. Cancer Cell 35, 1–18 (2019)
Y. Zhuang, R.C. Ly, C.V. Frazier, J. Yu, S. Qin, X.-Y. Fan, M.P. Goetz, J.C. Boughey, R. Weinshilboum, L. Wang, The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer. Cancer Metabol. 7, 1 (2019)
S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A. Consensus, Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14, 552–561 (2018)